keyword
MENU ▼
Read by QxMD icon Read
search

colorectal cancer chemotherapy

keyword
https://www.readbyqxmd.com/read/28722671/can-polysaccharide-k-improve-therapeutic-efficacy-and-safety-in-gastrointestinal-cancer-a-systematic-review-and-network-meta-analysis
#1
Yan Ma, Xiaofen Wu, Jingwen Yu, Jinyan Zhu, Xia Pen, Xianjun Meng
OBJECTIVE: To assess the comparative efficacy and safety of polysaccharide K (PSK), with or without chemotherapy, for patients with gastrointestinal cancer (GIC) through a systematic review and network meta-analysis. MATERIALS AND METHODS: We performed a network meta-analysis to identify evidence from randomized controlled trials. We searched PubMed, Embase and the Cochrane Library for publications up to May 2017. The prespecified primary efficacy outcomes were 1-7 year overall survival (OS), while the secondary efficacy outcomes were 1-7 year disease-free survival (DFS); we performed subgroup analyses and meta-regressions according to the cancer type (colorectal, esophagus and gastric cancer) and treatment arms (with or without chemotherapy)...
July 6, 2017: Oncotarget
https://www.readbyqxmd.com/read/28721456/antiangiogenic-tyrosine-kinase-inhibitors-in-colorectal-cancer-is-there-a-path-to-making-them-more-effective
#2
REVIEW
Thomas B Karasic, Mark A Rosen, Peter J O'Dwyer
Antiangiogenic therapy has a proven survival benefit in metastatic colorectal cancer. Inhibition of the VEGF pathway using a variety of extracellular antibody approaches has clear benefit in combination with chemotherapy, while intracellular blockade using tyrosine kinase inhibitors (TKIs) such as sorafenib and regorafenib has had more limited success. Pharmacodynamic modeling using modalities such as DCE-MRI indicates potent antiangiogenic effects of these TKIs, yet numerous combination therapies, primarily with chemotherapy, have failed to demonstrate an additive benefit...
July 18, 2017: Cancer Chemotherapy and Pharmacology
https://www.readbyqxmd.com/read/28721098/patient-selection-for-cytoreductive-surgery-and-hipec-for-the-treatment-of-peritoneal-metastases-from-colorectal-cancer
#3
REVIEW
Geert A Simkens, Koen P Rovers, Simon W Nienhuijs, Ignace H de Hingh
Cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) is a viable option for selected patients with peritoneal metastases (PM) from colorectal origin, resulting in long-term survival and even cure in some cases. However, adequate patient selection for this treatment is currently one of the major challenges. The aim of this review is to provide a comprehensive overview of clinically relevant factors associated with overall survival. This may help to guide clinicians through the complex interplay of patient, tumor, and treatment characteristics to adequately select patients who benefit the most from this extensive surgical treatment...
2017: Cancer Management and Research
https://www.readbyqxmd.com/read/28720258/feasibility-and-acceptability-of-the-use-of-patient-reported-outcome-measures-proms-in-the-delivery-of-nurse-led-supportive-care-to-people-with-colorectal-cancer
#4
Grigorios Kotronoulas, Constantina Papadopoulou, Lorna MacNicol, Mhairi Simpson, Roma Maguire
PURPOSE: Logistical issues pertinent to the use of patient-reported outcome measures (PROMs) by colorectal cancer nurse specialists (CNS) to identify the needs of people with colorectal cancer (CRC) in acute care remain unknown. We explored the feasibility and acceptability of PROMs-driven, CNS-led consultations to enhance delivery of supportive care to people with CRC completing adjuvant chemotherapy. METHODS: A systematic literature review and focus groups with patients and CNS (Phase 1) were followed by a repeated-measures, exploratory study (Phase 2), whereby pre-consultation PROM data were collected during three consecutive, monthly consultations, and used by the CNS to enable delivery of personalised supportive care...
August 2017: European Journal of Oncology Nursing: the Official Journal of European Oncology Nursing Society
https://www.readbyqxmd.com/read/28717759/quality-oncology-practice-initiative-can-guide-and-improve-oncology-providers-training-in-brazil
#5
Cristiane Decat Bergerot, Errol J Philip, Paulo Gustavo Bergerot, Simone Elias, Daiane Pereira Guimarães, Nora Manoukian Forones, Otavio Cesar Carvalho Guimarães Baiocchi, Nildo Alves Batista, Edvane Birelo Lopes De Domenico
PURPOSE: It has become crucial to translate scientific findings and to find ways by which to mobilize local resources to improve the quality and accessibility of cancer care in developing countries. This study seeks to provide insight into challenge through examining differences in clinician documentation of patients with cancer treated at a Brazilian Public University Hospital. METHODS: ASCO Quality Oncology Practice Initiative (QOPI) measures were used to examine the care provided in the departments of breast, colorectal, lymphoma, gynecology, and lung cancers...
June 2017: Journal of Global Oncology
https://www.readbyqxmd.com/read/28717739/liver-metastasectomy-and-systemic-therapy-improve-overall-survival-compared-with-surgery-alone-after-curative-liver-resection-of-colorectal-metastases-in-a-developing-country-costa-rica
#6
Paula Quesada-Soto, Denis Landaverde, Allan Ramos-Esquivel
BACKGROUND: Resection of liver-isolated metastases of colorectal cancer (CRC) offers the greatest likelihood of cure. Nevertheless, recurrence rates after this procedure are high, and chemotherapy is a reasonable choice with inconclusive evidence. We aimed to determine if there is a survival difference between patients receiving systemic therapy with surgery versus surgery alone for resection of liver metastases. METHODS: From a source population of 170 patients treated in our National Centre (Centro Nacional de Cirugía Hepatobiliar, San José, Costa Rica), with liver metastases from various primary sites, we selected 51 patients with CRC who underwent hepatic resection with curative intent...
February 2017: Journal of Global Oncology
https://www.readbyqxmd.com/read/28715968/applications-of-hyperthermic-intraperitoneal-chemotherapy-for-metastatic-colorectal-cancer
#7
Matthias Hornung, Jens M Werner, Hans J Schlitt
Cytoreductive surgery (CRS) combined with hyperthermic intraperitoneal chemotherapy (HIPEC) plays a pivotal role in the current treatment of peritoneal carcinomatosis (PC) from colorectal cancer (CRC). Since the first demonstration, benefits for patients and especially an increase in survival have been described. In recent years, feasibility, efficacy and safety of HIPEC have been improved and progress has been made in understanding its oncological mechanism. Areas Covered: In this article, leading publications have been reviewed including clinical trials to describe the clinical presentation of PC due to CRC and present recent evidence of the CRS/HIPEC procedure...
July 18, 2017: Expert Review of Anticancer Therapy
https://www.readbyqxmd.com/read/28715540/predictors-of-hand-foot-syndrome-and-pyridoxine-for-prevention-of-capecitabine-induced-hand-foot-syndrome-a-randomized-clinical-trial
#8
Yoon-Sim Yap, Li-Lian Kwok, Nicholas Syn, Wen Yee Chay, John Whay Kuang Chia, Chee Kian Tham, Nan Soon Wong, Soo Kien Lo, Rebecca Alexandra Dent, Sili Tan, Zuan Yu Mok, King Xin Koh, Han Chong Toh, Wen Hsin Koo, Marie Loh, Raymond Chee Hui Ng, Su Pin Choo, Richie Chuan Teck Soong
Importance: Hand-foot syndrome (HFS) is a common adverse effect of capecitabine treatment. Objective: To compare the incidence and time to onset of grade 2 or greater HFS in patients receiving pyridoxine vs placebo and to identify biomarkers predictive of HFS. Design, Setting, and Participants: This single-center, randomized double-blind, placebo-controlled phase 3 trial conducted at National Cancer Centre Singapore assessed whether oral pyridoxine could prevent the onset of grade 2 or higher HFS in 210 patients scheduled to receive single-agent capecitabine chemotherapy for breast, colorectal, and other cancers...
July 13, 2017: JAMA Oncology
https://www.readbyqxmd.com/read/28714940/non-coding-rnas-as-predictive-biomarkers-to-current-treatment-in-metastatic-colorectal-cancer
#9
REVIEW
Ingrid Garajová, Manuela Ferracin, Elisa Porcellini, Andrea Palloni, Francesca Abbati, Guido Biasco, Giovanni Brandi
The onset and selection of resistant clones during cancer treatment with chemotherapy or targeted therapy is a major issue in the clinical management of metastatic colorectal cancer patients. It is possible that a more personalized treatment selection, using reliable response-to-therapy predictive biomarkers, could lead to an improvement in the success rate of the proposed therapies. Although the process of biomarker selection and validation could be a long one, requiring solid statistics, large cohorts and multicentric validations, non-coding RNAs (ncRNAs) and in particular microRNAs, proved to be extremely promising in this field...
July 17, 2017: International Journal of Molecular Sciences
https://www.readbyqxmd.com/read/28714365/conjugation-of-gold-nanoparticles-and-recombinant-human-endostatin-modulates-vascular-normalization-via-interruption-of-anterior-gradient-2-mediated-angiogenesis
#10
Fan Pan, Wende Yang, Wei Li, Xiao-Yan Yang, Shuhao Liu, Xin Li, Xiaoxu Zhao, Hui Ding, Li Qin, Yunlong Pan
Several studies have revealed the potential of normalizing tumor vessels in anti-angiogenic treatment. Recombinant human endostatin is an anti-angiogenic agent which has been applied in clinical tumor treatment. Our previous research indicated that gold nanoparticles could be a nanoparticle carrier for recombinant human endostatin delivery. The recombinant human endostatin-gold nanoparticle conjugates normalized vessels, which improved chemotherapy. However, the mechanism of recombinant human endostatin-gold nanoparticle-induced vascular normalization has not been explored...
July 2017: Tumour Biology: the Journal of the International Society for Oncodevelopmental Biology and Medicine
https://www.readbyqxmd.com/read/28712102/precision-medicine-in-metastatic-colorectal-cancer-relevant-carcinogenic-pathways-and-targets-part-2-approaches-beyond-first-line-therapy-and-novel-biologic-agents-under-investigation
#11
REVIEW
Benjamin A Weinberg, Marion L Hartley, Mohamed E Salem
A frequent quandary for oncologists is the selection of chemotherapy and biologic therapy for patients with metastatic colorectal cancer in second-line and higher treatment settings. While not approved by the US Food and Drug Administration (FDA) in the first-line setting, the vascular endothelial growth factor (VEGF)-targeting agents ziv-aflibercept and ramucirumab are appropriate treatment options in the second-line setting, as is continuation of first-line bevacizumab. Tumor RAS mutational status is helpful to determine which patients may benefit from epidermal growth factor receptor (EGFR)-directed therapies, and other novel biomarkers (BRAF, HER2, and mismatch repair deficiency) allow us to select patients who may benefit from biologic therapies that are FDA-approved for other malignancies...
July 15, 2017: Oncology (Williston Park, NY)
https://www.readbyqxmd.com/read/28712098/precision-medicine-in-metastatic-colorectal-cancer-relevant-carcinogenic-pathways-and-targets-part-1-biologic-therapies-targeting-the-epidermal-growth-factor-receptor-and-vascular-endothelial-growth-factor
#12
REVIEW
Benjamin A Weinberg, Marion L Hartley, Mohamed E Salem
The survival of patients with metastatic colorectal cancer has improved dramatically in recent years, with overall survival exceeding 3 years in large randomized clinical trials. There are now several treatment options for patients with metastatic colorectal cancer. In addition to chemotherapy backbones utilizing fluoropyrimidine, oxaliplatin, and irinotecan combinations, biologic agents that target specific oncogenic pathways have contributed to the improved survival observed in this patient population. This class of medications includes epidermal growth factor receptor (EGFR)-targeted drugs (cetuximab and panitumumab) and vascular endothelial growth factor (VEGF)-targeted therapies (bevacizumab, ramucirumab, ziv-aflibercept, and regorafenib)...
July 15, 2017: Oncology (Williston Park, NY)
https://www.readbyqxmd.com/read/28710725/clinicopathologic-parameters-associated-with-postoperative-complications-and-risk-factors-for-tumor-recurrence-and-mortality-after-tumor-resection-of-patients-with-colorectal-cancer
#13
Z Bai, J Wang, T Wang, Y Li, X Zhao, G Wu, Y Yang, W Deng, Z Zhang
OBJECTIVE: To delineate the association of postoperative complications with clinicopathologic factors and to identify risk factors for tumor recurrence and mortality after tumor resection in patients with colorectal cancer (CRC). METHODS: The clinical data of 1144 patients with CRC who underwent surgical intervention between 2003 and 2013 were retrieved. Correlations of postoperative complications with clinicopathologic factors were examined using univariate analysis...
July 14, 2017: Clinical & Translational Oncology
https://www.readbyqxmd.com/read/28709876/is-cure-possible-after-sequential-resection-of-hepatic-and-pulmonary-metastases-from-colorectal-cancer
#14
Muthukumarassamy Rajakannu, Pierre Magdeleinat, Eric Vibert, Oriana Ciacio, Gabriella Pittau, Pasquale Innominato, Antonio SaCunha, Daniel Cherqui, Jean-François Morère, Denis Castaing, René Adam
BACKGROUND: Surgical resection is an established therapeutic strategy for colorectal cancer (CRC) metastasis. However, controversies exist when CRC liver and lung metastases (CLLMs) are found concomitantly or when recurrence develops after either liver or lung resection. No predictive score model is available to risk stratify these patients in preparation for surgery, and cure has not yet been reported. PATIENTS AND METHODS: All consecutive patients who had undergone surgery for CLLMs at our institution during a 20-year period were reviewed...
June 23, 2017: Clinical Colorectal Cancer
https://www.readbyqxmd.com/read/28709052/colon-cancer-metastasis-to-the-thyroid-gland-a-case-report
#15
M I Coelho, M N Albano, C E Costa Almeida, L S Reis, N Moreira, C M C Almeida
INTRODUCTION: Thyroid metastases from colorectal cancer are uncommon and few cases are described in literature. CASE PRESENTATION: A 64-year-old female patient presented with an asymptomatic right cervical nodule with a rapid growth six years after sigmoidectomy for cancer and two years after resection of colorectal lung metastases. Increased CA 19.9 was identified and a thoracoabdominal CT scan revealed the onset of new metastatic bilateral pulmonary lesions. Neck ultrasonography showed a suspicious nodule in the right thyroid lobe, and Fine-needle Aspiration Cytology (FNAC) of the nodule lead to the diagnosis of colorectal cancer metastasis...
June 28, 2017: International Journal of Surgery Case Reports
https://www.readbyqxmd.com/read/28708932/tandem-repeat-variation-near-the-hic1-hypermethylated-in-cancer-1-promoter-predicts-outcome-of-oxaliplatin-based-chemotherapy-in-patients-with-metastatic-colorectal-cancer
#16
Satoshi Okazaki, Marta Schirripa, Fotios Loupakis, Shu Cao, Wu Zhang, Dongyun Yang, Yan Ning, Martin D Berger, Yuji Miyamoto, Mitsukuni Suenaga, Syma Iqubal, Afsaneh Barzi, Chiara Cremolini, Alfredo Falcone, Francesca Battaglin, Lisa Salvatore, Beatrice Borelli, Timothy G Helentjaris, Heinz-Josef Lenz
BACKGROUND: The hypermethylated in cancer 1/sirtuin 1 (HIC1/SIRT1) axis plays an important role in regulating the nucleotide excision repair pathway, which is the main oxaliplatin-induced damage-repair system. On the basis of prior evidence that the variable number of tandem repeat (VNTR) sequence located near the promoter lesion of HIC1 is associated with HIC1 gene expression, the authors tested the hypothesis that this VNTR is associated with clinical outcome in patients with metastatic colorectal cancer who receive oxaliplatin-based chemotherapy...
July 14, 2017: Cancer
https://www.readbyqxmd.com/read/28708138/blocking-endothelin-1-receptor-%C3%AE-catenin-circuit-sensitizes-to-chemotherapy-in-colorectal-cancer
#17
Roberta Cianfrocca, Laura Rosanò, Piera Tocci, Rosanna Sestito, Valentina Caprara, Valeriana Di Castro, Ruggero De Maria, Anna Bagnato
The limited clinical response to conventional chemotherapeutics observed in colorectal cancer (CRC) may be related to the connections between the hyperactivated β-catenin signaling and other pathways in CRC stem-like cells (CRC-SC). Here, we show the mechanistic link between the endothelin-1 (ET-1)/ET-1 receptor (ET-1R) signaling and β-catenin pathway through the specific interaction with the signal transducer β-arrestin1 (β-arr1), which initiates signaling cascades as part of the signaling complex. Using a panel of patient-derived CRC-SC, we show that these cells secrete ET-1 and express ETAR and β-arr1, and that the activation of ETAR/β-arr1 axis promotes the cross-talk with β-catenin signaling to sustain stemness, epithelial-to-mesenchymal transition (EMT) phenotype and response to chemotherapy...
July 14, 2017: Cell Death and Differentiation
https://www.readbyqxmd.com/read/28707587/immunotherapeutic-interleukin-6-or-interleukin-6-receptor-blockade-in-cancer-challenges-and-opportunities
#18
Nirmala C Kampan, Sue D Xiang, Orla M McNally, Andrew N Stephens, Michael A Quinn, Magdalena Plebanski
Interleukin 6 (IL-6), a well-known pro-inflammatory cytokine with pleiotropic activity is a central player in chronic inflammatory diseases including cancers. Therefore, blockade of the IL-6 signaling pathway has become a target for the therapy of in diverse cancers such as multicentric Castleman's disease (CD), multiple myeloma and solid tumours including renal, prostate, lung, colorectal and ovarian cancers. Monoclonal antibodies against IL-6 (Siltuximab) and the IL-6 receptor (IL-6R) (Tocilizumab) have emerged as potential immunotherapies, alone or in combination with conventional chemotherapy...
July 12, 2017: Current Medicinal Chemistry
https://www.readbyqxmd.com/read/28705789/treatment-of-peritoneal-dissemination-in-stomach-cancer-patients-with-cytoreductive-surgery-and-hyperthermic-intraperitoneal-chemotherapy-hipec-rationale-and-design-of-the-periscope-study
#19
Rosa T van der Kaaij, Hidde Jw Braam, Henk Boot, Maartje Los, Annemieke Cats, Cecile Grootscholten, Jan Hm Schellens, Arend Gj Aalbers, Alwin Dr Huitema, Catherijne Aj Knibbe, Djamila Boerma, Marinus J Wiezer, Bert van Ramshorst, Johanna W van Sandick
BACKGROUND: Patients with gastric cancer and peritoneal carcinomatosis have a very poor prognosis; median survival is 3 to 4 months. Palliative systemic chemotherapy is currently the only treatment available in the Netherlands. Intraoperative hyperthermic intraperitoneal chemotherapy (HIPEC) has an established role in the treatment of peritoneal carcinomatosis originating from colorectal cancer, appendiceal cancer, and pseudomyxoma peritonei; its role in gastric cancer is uncertain. Currently, there is no consensus on the choice of chemotherapeutic agents used in HIPEC for gastric cancer...
July 13, 2017: JMIR Research Protocols
https://www.readbyqxmd.com/read/28702182/effect-of-adjuvant-chemotherapy-after-pulmonary-metastasectomy-on-the-prognosis-of-colorectal-cancer
#20
Kazu Shiomi, Masanori Naito, Takeo Sato, Takatoshi Nakamura, Hiroyasu Nakashima, Masahito Naito, Masashi Mikubo, Yoshio Matsui, Masahiko Watanabe, Yukitoshi Satoh
BACKGROUND: Adjuvant chemotherapy after resection of colorectal cancer (CRC) lung metastases may reduce recurrences and improve survival. We investigated the effects of adjuvant chemotherapy after curative resection of lung CRC metastases on prognosis. METHODS: We retrospectively reviewed records of our patients undergoing pulmonary metastasectomy from CRC between January 2000-March 2014. Data were analyzed with Kaplan-Meier survival analysis and Cox proportional hazards models...
August 2017: Annals of Medicine and Surgery
keyword
keyword
40932
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"